Better Developmental function at 3 years for infants born at 22-23wks who participated in the Randomized Controlled Trial for the Prevention of Intraventricular Hemorrhage by Indomethacin in Japanese Extremely Low Birthweight Infants. SHINYA HIRANO, M.D. 1 ） MASANORI FUJIMURA, M.D. 1 ）
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
Better Developmental function at 3 years for infants born at 22-23wks who participated in the Randomized Controlled Trial for the Prevention of Intraventricular Hemorrhage by Indomethacin in Japanese Extremely Low Birthweight Infants
SHINYA HIRANO, M.D.1）MASANORI FUJIMURA, M.D.1）
Neonatal Research Network Japan
1）Department of Neonatal Medicine,
Osaka Medical Center for Maternal and Child Health,
Izumi, Osaka, Japan.
718 infants assessed for eligibility
50 : Excluded
67 : Not approached
In- / Out-born
Apgar at 1min
601 infants eligible
132 : No consent
Death : 29
Drop out, No data : 18
Death : 22
Drop out, No data : 22
378 / 418
IVH Grade III or IV within 7days
odds ratio (95% CI) 0.37 (0.18-0.77)
effective to prevent severe Intraventricular hemorrhage (IVH)
Cerebral palsy and/or Death around 3 years
did not reduce the incidence of CP and/or Death
Incidence of IVH Grede III or IV and “CP or Death “
stratified by Birth weight group
the incidence of “severe IVH” and “CP or death” significantly reduced in 400-599g
Stratified by gestational weeks
Seem to be effective to reduce “severe IVH” and “CP or death” in 22-23wks
【 Objective 】
To compare the developmental quotient (DQ) using the Kyoto Scale of Psychological Development (KSPD) at 3 years between the two groups (IND or placebo) in follow-up study.
Death : 22
Drop out or no data: 22
Death : 29
Drop out or no data: 18
Kyoto Scale of Psychological Development (KSPD) at 3 years
Baseline Characteristics 1
Baseline Characteristics 2
Comparison of KSPD -DQ
171 160 161157168 161 168 161
Comparison of Total Score DQ - by Birthweight group
p=0.92 p=0.26 p=0.16
1410115107 42 43
Comparison of Total Score DQ -categorized by G.W.
p=0.042 p=0.06 p=0.06
12 9101 88 67 72
Dr. NAME has disclosed the following financial relationships. Any real or apparent conflicts of interest related to the content of this presentation have been resolved.
Presenter:NAME has documented that his/her presentation will not involve discussion of unapproved or off-label, experimental or investigational use.
Presenter:NAME has documented that his/her presentation involves comments or discussion of unapproved or off-label, experimental or investigational use of <<identify products, drugs or devices>>.